Latest news about bimetinib/bemetinib in 2025

CanafenibThe efficacy and safety of Canafenib/Encorafenib-Braftovi plus Binimetinib/Binimetinib-Mektovi in the treatment of patients with BRAF V600E mutated metastatic non-small cell lung cancer (NSCLC) is being evaluated in the Phase 2 PHAROS study. According to the latest follow-up data, the combination therapy continues to exhibit significant anti-tumor activity after at least 32 months of follow-up in patients who received initial treatment.

The study results showed that the overall response rate (ORR) of patients treated with canelfenib and bimetinib reached 75%. In addition, the median duration of response (DOR) was 40.0 months, demonstrating a good response to the treatment. The median progression-free survival (PFS) is 30.2 months, while overall survival (OS) has not yet been effectively estimated.

Compared with historical data, the clinical results of this combination therapy in patients with BRAF V600E mutant metastatic non-small cell lung cancer continue to be excellent, further confirming its potential to improve patient prognosis. Median OS has reached 22.7 months, demonstrating the long-term benefits of treatment.

In the group of patients who had previously received other treatments, the combination of encorafenib and binimetinib also showed a similar safety profile after at least 22 months of follow-up, and no new safety signals were identified, indicating that the safety profile of this treatment regimen is consistent with the results of the previous preliminary analysis. This stable safety record provides a more reliable basis for clinical application of this combination therapy.

In summary, the combination treatment of bimetinib and canafenib demonstrated outstanding anti-tumor activity and acceptable safety in patients with BRAF V600E mutated metastatic non-small cell lung cancer. This provides a new treatment option for relevant patients and may improve their survival prognosis. Researchers will continue to monitor the long-term effects of this treatment and its applicability to other patient groups.

Reference materials:https://www.onclive.com/view/updated-efficacy-and-safety-from-the-phase-2-pharos-study-of-encorafenib-plus-binimetinib-in-patients-with-braf-v600e-mutant-metastatic-nsclc-mnsclc-